- TRADE NAME: Xerava (Tetraphase Pharms Inc)
- INDICATIONS: treatment of complicated intra-abdominal infections in patients 18 years of age and older.
- CLASS: Antibiotic, Antibiotic; tetracycline
- HALF-LIFE: 20 hours
- FDA APPROVAL DATE: 08/27/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: data insufficient to inform drug-associated risk of major birth defects and miscarriages.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
